YA_MESMA
ID YA_MESMA Reviewed; 200 AA.
AC Q9Y0X6;
DT 16-OCT-2013, integrated into UniProtKB/Swiss-Prot.
DT 16-OCT-2013, sequence version 2.
DT 25-MAY-2022, entry version 31.
DE RecName: Full=BmK-YA precursor {ECO:0000303|PubMed:22792309};
DE Contains:
DE RecName: Full=BmK-YA 1 {ECO:0000303|PubMed:22792309};
DE AltName: Full=Enkephalin-like peptide 1 {ECO:0000303|PubMed:22792309};
DE Contains:
DE RecName: Full=BmK-YA 2 {ECO:0000303|PubMed:22792309};
DE AltName: Full=Enkephalin-like peptide 2 {ECO:0000303|PubMed:22792309};
DE Contains:
DE RecName: Full=BmK-YA 3 {ECO:0000303|PubMed:22792309};
DE AltName: Full=Enkephalin-like peptide 3 {ECO:0000303|PubMed:22792309};
DE Contains:
DE RecName: Full=BmK-YA 4 {ECO:0000303|PubMed:22792309};
DE AltName: Full=Enkephalin-like peptide 4 {ECO:0000303|PubMed:22792309};
DE Flags: Precursor;
OS Mesobuthus martensii (Manchurian scorpion) (Buthus martensii).
OC Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Chelicerata; Arachnida;
OC Scorpiones; Buthida; Buthoidea; Buthidae; Mesobuthus.
OX NCBI_TaxID=34649;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 35-42; 101-108; 145-152 AND
RP 189-196, SYNTHESIS, FUNCTION, SUBCELLULAR LOCATION, MASS SPECTROMETRY,
RP AMIDATION AT ALA-42; ALA-108; ALA-152 AND ALA-196, AND MUTAGENESIS OF
RP TYR-38; TYR-104; TYR-148 AND TYR-192.
RC TISSUE=Venom;
RX PubMed=22792309; DOI=10.1371/journal.pone.0040417;
RA Zhang Y., Xu J., Wang Z., Zhang X., Liang X., Civelli O.;
RT "BmK-YA, an enkephalin-like peptide in scorpion venom.";
RL PLoS ONE 7:E40417-E40417(2012).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 106-200.
RC TISSUE=Venom gland;
RA Wenxin L., Shunyi Z.;
RL Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
CC -!- FUNCTION: Synthetic BmK-YA activates human opioid receptors in vitro,
CC with highest activity on the delta-type/OPRD1 receptor (EC(50)=2.5 uM)
CC and lower activity on mu-type/OPRM1 and kappa-type/OPRK1 receptors
CC (EC(50)=17 uM and 30 uM, respectively). {ECO:0000269|PubMed:22792309}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:22792309}.
CC -!- TISSUE SPECIFICITY: Venom gland. {ECO:0000305|PubMed:22792309}.
CC -!- MASS SPECTROMETRY: Mass=871.3; Method=Electrospray; Note=The measured
CC ranges are 35-42, 101-108, 145-152, 189-196.;
CC Evidence={ECO:0000269|PubMed:22792309};
CC -!- MISCELLANEOUS: Four additional, similar peptides (containing a
CC substitution of Tyr-4 to His-4) are predicted from this sequence:
CC however, there is no evidence that they exist in vivo and the synthetic
CC peptide has no known function. {ECO:0000269|PubMed:22792309,
CC ECO:0000305}.
CC -!- SEQUENCE CAUTION:
CC Sequence=AAD39510.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF146742; AAD39510.1; ALT_INIT; mRNA.
DR AlphaFoldDB; Q9Y0X6; -.
DR PRIDE; Q9Y0X6; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0001515; F:opioid peptide activity; IDA:CACAO.
DR GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
PE 1: Evidence at protein level;
KW Amidation; Direct protein sequencing;
KW G-protein coupled receptor impairing toxin; Secreted; Signal; Toxin.
FT SIGNAL 1..23
FT /evidence="ECO:0000255"
FT PROPEP 24..34
FT /evidence="ECO:0000269|PubMed:22792309"
FT /id="PRO_0000423811"
FT PEPTIDE 35..42
FT /note="BmK-YA 1"
FT /evidence="ECO:0000269|PubMed:22792309"
FT /id="PRO_0000423812"
FT PROPEP 45..100
FT /evidence="ECO:0000269|PubMed:22792309"
FT /id="PRO_0000423813"
FT PEPTIDE 101..108
FT /note="BmK-YA 2"
FT /evidence="ECO:0000269|PubMed:22792309"
FT /id="PRO_0000423814"
FT PROPEP 111..144
FT /evidence="ECO:0000269|PubMed:22792309"
FT /id="PRO_0000423815"
FT PEPTIDE 145..152
FT /note="BmK-YA 3"
FT /evidence="ECO:0000269|PubMed:22792309"
FT /id="PRO_0000423816"
FT PROPEP 155..188
FT /evidence="ECO:0000269|PubMed:22792309"
FT /id="PRO_0000423817"
FT PEPTIDE 189..196
FT /note="BmK-YA 4"
FT /evidence="ECO:0000269|PubMed:22792309"
FT /id="PRO_0000423818"
FT PROPEP 199..200
FT /evidence="ECO:0000269|PubMed:22792309"
FT /id="PRO_0000423819"
FT REGION 30..200
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 42
FT /note="Alanine amide"
FT /evidence="ECO:0000269|PubMed:22792309"
FT MOD_RES 108
FT /note="Alanine amide"
FT /evidence="ECO:0000269|PubMed:22792309"
FT MOD_RES 152
FT /note="Alanine amide"
FT /evidence="ECO:0000269|PubMed:22792309"
FT MOD_RES 196
FT /note="Alanine amide"
FT /evidence="ECO:0000269|PubMed:22792309"
FT MUTAGEN 38
FT /note="Y->F: Increased potency on delta-type, mu-type and
FT kappa-type opioid receptors."
FT /evidence="ECO:0000269|PubMed:22792309"
FT MUTAGEN 104
FT /note="Y->F: Increased potency on delta-type, mu-type and
FT kappa-type opioid receptors."
FT /evidence="ECO:0000269|PubMed:22792309"
FT MUTAGEN 148
FT /note="Y->F: Increased potency on delta-type, mu-type and
FT kappa-type opioid receptors."
FT /evidence="ECO:0000269|PubMed:22792309"
FT MUTAGEN 192
FT /note="Y->F: Increased potency on delta-type, mu-type and
FT kappa-type opioid receptors."
FT /evidence="ECO:0000269|PubMed:22792309"
SQ SEQUENCE 200 AA; 22968 MW; 19E74AF01166CF5E CRC64;
MIFHQFYSIL ILCLIFPNQV VQSDKERQDW IPSDYGGYMN PAGRSDEERQ DWIPSDYGGH
MNPAGRSDEE RQDWIPSDYG GHMNPAGRSN EERQDWIPSD YGGYMNPAGR SDEERQDWIP
SDYGGHMNPA GRSNEERQDW IPSDYGGYMN PAGRSDEERQ DWIPSDYGGH MNPAGRSDEE
RQDWIPSDYG GYMNPAGRSD
